All In Biotech

Drug Trial Radar · NCT01624662

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

A 16-Week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (Bid) Using a Novel Bi-directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-week, Open-label Extension Phase to Assess Safety

Last checked: Nov 19, 2026Latest source record: Dec 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Oct 30, 2013

Primary completion

May 11, 2015

Study completion Jul 3, 2015

Sponsor

Lead sponsor
Optinose US Inc.Industry
Sponsor type
Industry
First posted
Jun 21, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to compare the efficacy of intranasal administration of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the Optinose device, with matching placebo in subjects with bilateral nasal polyposis and nasal congestion.

Conditions

  • Bilateral Nasal Polyposis

Interventions

  • Fluticasone propionateDrug

    Delivered via Optinose Exhalation Delivery System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction SymptomsTime frame: Baseline, Week 4 of the double-blind treatment phase
  2. Change in Total Polyp GradeTime frame: Baseline, Week 16 of the double-blind treatment phase

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Bensch Clinical Research LLC

    Stockton, California

  • Colorado Allergy & Asthma Centers, PC

    Centennial, Colorado

  • Advanced ENT and Allergy

    Louisville, Kentucky

  • Institute for Asthma and Allergy

    Wheaton, Maryland

  • Atlantic Research Center, LLC

    Ocean City, New Jersey

  • Allergy and Asthma Research Group

    Eugene, Oregon

  • Baker Allergy, Asthma and Dermatology Research Center, LLC

    Lake Oswego, Oregon

  • Valley Clinical Research Center

    Bethlehem, Pennsylvania

  • University of Vermont

    Burlington, Vermont

  • Bellingham Asthma, Allergy, and Immunology Clinic

    Bellingham, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.